NDAORALCAPSULEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LYNPARZA (olaparib) by AstraZeneca is poly(adp-ribose) polymerase inhibitors [moa]. Approved for ovarian cancer, breast cancer, prostate cancer and 3 more indications. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNPARZA (olaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved by the FDA in December 2014 for treating BRCA-mutated cancers and other homologous recombination deficiency-associated malignancies. The drug works by inhibiting PARP enzymes, which are critical for DNA repair, thereby causing synthetic lethality in tumor cells with defective DNA repair pathways. LYNPARZA is positioned as a foundational therapy in precision oncology, particularly for ovarian, breast, and pancreatic cancers with specific genomic signatures.
$0.5BPart D
5.2 years to LOEMechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Indications (6)
Worked on LYNPARZA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.